Business

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 6, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage bio...

articleNrx Pharmaceuticals, Inc.June 6, 20254/company/nrx-pharmaceuticals-inc/news/ibn-coverage-nrx-pharmaceuticals-nasdaq-nrxp-signs-agreement-to-acquire-kadima-to-launch-dollar100m-psychiatry-clinic-network
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

About this update from Nrx Pharmaceuticals, Inc.

[{"type":"text","content":"This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.","length":145,"tagName":"p"},{"type":"text","content":"LOS ANGELES, CA - June 6, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, known for treating suicidal bipolar depression and acute suicidal depression, has signed a definitive agreement to acquire Kadima Neuropsychiatry Institute. The Kadima acquisition agreement (not yet closed) is part of HOPE's strategy to establish a scalable mental health treatment network of interventional psychiatry clinics. (https://ibn.fm/DjOMz).","length":483,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics' model for a planned national clinic network, and is expected to immediately improve revenue and EBITDA for NRx and HOPE Therapeutics.","length":231,"tagName":"p"}]},{"val":[{"type":"text","content":"HOPE aims to develop a network of up to 30 interventional psychiatry clinics by the end of 2025, with a $100 million pro forma run rate by YE 25.","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"Kadima specializes in interventional psychiatry, and Kadima's founder Dr. David Feifel, will join HOPE as Chief Medical Innovation Officer.","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"NRx's broader pipeline includes FDA-designated treatments for bipolar depression and acute suicidality.","length":107,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":626,"olType":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1400,"height":800,"url":"https://media.zenfs.com/en/newsmediawire_165/176e8941c94808aff9c938d472630a9d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/f0t0bTfV_CQY6oMk1_54vg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0OTtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/176e8941c94808aff9c938d472630a9d","width":960,"height":549},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/i9X7sGC08kCH4Q5xzgPrJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzcyO2NmPXdlYnA-/https://media.zenfs.com/en/newsmed...

More updates from Nrx Pharmaceuticals, Inc.

suicidal depressionKadimabipolar depressioninterventional psychiatrybiopharmaceutical companydefinitive agreementcontent creationproposed networkclinic networkforward-looking statements